World's first vaccine trial against elephant endotheliotropic herpesvirus proves safe and effective
The vaccine trial in adult elephants showed no side effects and induced a strong immune response, a key step toward protecting vulnerable calves from EEHV, which kills over 80% of infected juveniles.
8 Articles
8 Articles
World's first vaccine trial against elephant endotheliotropic herpesvirus proves safe and effective
The world's first vaccine trial against elephant endotheliotropic herpesvirus (EEHV) – a leading cause of death in young Asian elephants – is safe and triggers a strong virus-fighting immune response, according to an international team led by the University of Surrey, in collaboration with Chester Zoo and the Animal and Plant Health Agency.
The first global test of an elephant herpes endotheliotropic virus (EHEV) vaccine, one of the leading causes of death among the offspring of this species, has triggered a strong immune response and seems to be effective. The entry Successfully test a herpes lethal vaccine for elephants was first published in the Digital Process.
Coverage Details
Bias Distribution
- 80% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium